Canadian cannabis stocks remain a bright spot in the cannabis stock market and investors need to focus on leading opportunities to be successful.

From international opportunities to emerging trends like smokeless products, Canadian cannabis producers have capitalizing from several emerging growth trends and we are favorable on this opportunity.

Today, we have highlighted three Canadian marijuana producers that are capitalizing on the global cannabis market and that investors need to be aware of.

Canopy Growth: Growing on a Third Continent

Canopy Growth (WEED.TO) (TWMJF) genetics are growing in soil on its third continent after successfully completing the transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA. The transfer of these plants completes the first phase of a partnership where Alcaliber will be producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes.

Canopy is currently the world’s largest and most diverse licensed medical marijuana producer and has a greater breadth of multi-site management than any other cannabis firm in the world, operating in seven countries internationally and servicing more than 70,000 medical marijuana patients in Canada as of December 31, 2017.

From Denmark to Chile, Australia to Germany, Canopy Growth has become a global cannabis leader. Although the shares have moved considerably higher over the last year, we remain bullish on the long-term outlook. Canopy Growth is capitalizing on a global movement that is barely in the first inning of a multi-decade growth cycle.

Canopy Growth remains one of the best long-term cannabis investment opportunities and is very well capitalized. The cannabis producer has the largest market share of Canada, received a $250 million investment from Constellation Brands (STZ), and continues to increase market share in legal cannabis markets across the globe.

MedReleaf: Enters Germany’s Medical Marijuana Market